Search

Your search keyword '"Kern, Johannes S."' showing total 347 results
Start Over Author "Kern, Johannes S."
347 results on '"Kern, Johannes S."'

1. Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients

Author

Dousset, Lea, Chambers, Daniel C., Webster, Angela, Isbel, Nicole, Campbell, Scott, Duarte, Carla, Collins, Louisa, Damian, Diona, Tseng, Anne, Karlsen, Emma, Ilinsky, Olga Victoria, Brown, Susan, Schaider, Helmut, Soyer, H. Peter, Ospino, Daniel Ariza, Hogarth, Sam, Chong, Alvin H., Mar, Victoria, McKenzie, Scott, Gin, Douglas, Fernandez-Penas, Pablo, Kern, Johannes S., Loewe, Katja, Roy, Edwige, Herschtal, Alan, and Khosrotehrani, Kiarash

Published
2024
Full Text
View/download PDF

3. The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) – Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions

Author

James, Fiona, Goh, Michelle S., Vogrin, Sara, Ng, Irvin, Douglas, Abby P., Holmes, Natasha E., Chua, Kyra YL., De Luca, Joseph, Sharma, Pooja, Zubrinich, Celia, Aung, Ar K., Gin, Douglas, Lambros, Belinda, Baker, Chris, Foley, Peter, Chong, Alvin H., Thien, Francis, Fok, Jie S., Su, John, Scardamaglia, Laura, Awad, Andrew, Tong, Steven, Johnson, Douglas, Godsell, Jack, Arasu, Alexis, Barnes, Sara, Ojaimi, Samar, Mar, Adrian, Yun, James, Ange, Nikhita, Tong, Winnie W.Y., Carr, Andrew, Loprete, Jacqueline, Katelaris, Constance H., Slape, Dana, Keat, Karuna, West, Timothy A., Lee, Monique, Smith, William, Hissaria, Pravin, Sidhu, Shireen, Janson, Sonja, Venkatesan, Sudharsan, Davies, Jane, Lane, Michael J., Redmond, Andrew M., Robertson, Ivan, Legg, Amy, Fernando, Suran, Boyle, Therese, Li, Jamma, Phillips, Elizabeth J., Cleland, Heather, Kern, Johannes S., and Trubiano, Jason A.

Published
2024
Full Text
View/download PDF

7. Evaluation and management of nail diseases.

Author

ARASU, ALEXIS, KERN, JOHANNES S., and HOWARD, ANNE

Subjects
*ONYCHOMYCOSIS, *NAIL diseases, *HIV infections, *SQUAMOUS cell carcinoma, *NAILS (Anatomy), *BOWEN'S disease, *MOHS surgery
Abstract

This article provides an overview of nail diseases and their management. It emphasizes the importance of recognizing and assessing changes in the nails, as they can indicate underlying systemic or localized diseases. The most common nail diseases seen in primary care include fungal infections, psoriasis, trauma, and melanonychia. Treatment can be challenging due to the anatomy of the nail and limited options available. The article also discusses various nail conditions, such as discoloration, thickening, thinning, pitting, pain, abnormal curvature, and grooves. It provides information on specific conditions like nail psoriasis, longitudinal melanonychia, Bowen's disease, myxoid pseudocysts, onychopapilloma, malalignment, and chronic paronychia. Treatment options include physical therapies, surgery, and environmental management. Recognizing the clinical features and seeking appropriate treatment is crucial for timely diagnosis and improved outcomes. [Extracted from the article]

Published
2024

8. Cutaneous Pathology of the Head and Neck

Author

Yap, Tami, Kern, Johannes S., Wood, Benjamin, Scardamaglia, Laura, Farah, Camile S., Section editor, Farah, Camile S., editor, Balasubramaniam, Ramesh, editor, and McCullough, Michael J., editor

Published
2019
Full Text
View/download PDF

10. CXCL17 induces activation of human mast cells via MRGPRX2.

Author

Ding, Jie, Hillig, Christina, White, Carl W., Fernandopulle, Nithya A., Anderton, Holly, Kern, Johannes S., Menden, Michael P., and Mackay, Graham A.

Subjects
TRYPTASE, MAST cells, ITCHING, MYELOID-derived suppressor cells, G protein coupled receptors, REGULATORY T cells, ANTIMICROBIAL peptides
Abstract

This article discusses the activation of mast cells (MCs) through the Mas-related G protein-coupled receptor X2 (MRGPRX2) pathway. The study focuses on the chemokine CXCL17, which is expressed in mucosal tissues and has antimicrobial properties. The researchers found that CXCL17 activates human MCs via the MRGPRX2 pathway, and this activation may be important in inflammatory conditions such as psoriasis. The study also provides evidence of increased expression of CXCL17 in psoriatic skin, particularly in areas proximal to MRGPRX2-positive MCs. Further research is needed to understand the role of CXCL17-induced MC activation in psoriasis and other inflammatory skin diseases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

14. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM)

Author

McComish, Jeremy S., primary, Slade, Charlotte A., additional, Buizen, Luke, additional, Paul, Sanjoy K., additional, Chatelier, Josh W., additional, Unglik, Gary, additional, Nicholls, Katherine A., additional, Spriggs, Kymble, additional, Chan, Samantha S., additional, Godsell, Jack, additional, Auyeung, Priscilla, additional, Tan, Zi Hao, additional, DeLuca, Joseph, additional, Patel, Mittal, additional, Kuek, Lin Eon, additional, Tran, Yang, additional, Kern, Johannes S., additional, Scardamaglia, Laura, additional, Varigos, George A., additional, Juneja, Surender, additional, Grabek, Julian A., additional, Christie, Michael, additional, Mackay, Graham A., additional, and Douglass, Jo A., additional

Published
2023
Full Text
View/download PDF

17. Management von bullösem Pemphigoid und Schleimhautpemphigoid.

Author

Kern, Johannes S. and Hofmann, Silke C.

Abstract

Copyright of Die Dermatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

21. CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa

Author

Gamell, Cristina, primary, Bankovacki, Aleksandra, additional, Scalzo-Inguanti, Karen, additional, Sedgmen, Bradley, additional, Alhamdoosh, Monther , additional, Gail, Emma, additional, Turkovic, Lydia, additional, Millar, Christine, additional, Johnson, Laura, additional, Wahlsten, Michelle, additional, Richter, Jim, additional, Schuster, Jared, additional, Dyson, Allison, additional, Nicolopoulos, Jenny, additional, Varigos, George , additional, Ng, Milica, additional, Wilson, Nick, additional, Field, Judith, additional, Kern, Johannes S, additional, and Lindqvist, Lisa M, additional

Published
2023
Full Text
View/download PDF

23. Clinical and dermoscopic features of nail unit melanoma in an Australian nail clinic cohort.

Author

Arasu, Alexis, Howard, Anne, Tan, Chin‐Guan, Prakash, Saurabh, and Kern, Johannes S.

Subjects
DERMOSCOPY, NAILS (Anatomy), NAIL diseases, MELANOMA, PROGNOSIS
Abstract

Nail unit melanoma carries diagnostic challenges conferring with its poor prognosis. This audit aims to characterise both clinical and dermoscopic features of nail unit malignant lesions and compare them with biopsied benign lesions. It focuses on informing future practice by aiding in the stratification and recognition of malignant diagnostic patterns in the Australian context. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR)

Author

James, Fiona, primary, Goh, Michelle S Y, additional, Mouhtouris, Effie, additional, Vogrin, Sara, additional, Chua, Kyra Y L, additional, Holmes, Natasha E, additional, Awad, Andrew, additional, Copaescu, Ana-Maria, additional, De Luca, Joseph F, additional, Zubrinich, Celia, additional, Gin, Douglas, additional, Cleland, Heather, additional, Douglas, Abby, additional, Kern, Johannes S, additional, Katelaris, Constance H, additional, Thien, Francis, additional, Barnes, Sara, additional, Yun, James, additional, Tong, Winnie, additional, Smith, William B, additional, Carr, Andrew, additional, Anderson, Tara, additional, Legg, Amy, additional, Bourke, Jack, additional, Mackay, Laura K, additional, Aung, Ar Kar, additional, Phillips, Elizabeth J, additional, and Trubiano, Jason, additional

Published
2022
Full Text
View/download PDF

29. Evaluation and management of nail diseases.

Author

ARASU, ALEXIS, KERN, JOHANNES S., and HOWARD, ANNE

Subjects
*DISEASE management, *NAIL diseases, *MEDICAL referrals, *DERMATOLOGISTS
Abstract

Nail disease is a common presentation in general practice. Recognising the clinical features of the various nail diseases can ensure that patient referrals to a dermatologist are prompt and that diagnosis and treatment are not delayed. [ABSTRACT FROM AUTHOR]

Published
2023

30. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.

Author

Kern, Johannes S, Sprecher, Eli, Fernandez, Maria Florencia, Schauer, Franziska, Bodemer, Christine, Cunningham, Tracy, Löwe, Sandra, Davis, Charles, Sumeray, Mark, Bruckner, Anna L, Murrell, Dédée F, and investigators, for the EASE

Subjects
*EPIDERMOLYSIS bullosa, *TRITERPENES, *BIRCH, *CHRONIC wounds & injuries, *SQUAMOUS cell carcinoma, *EARLY death
Abstract

Background Epidermolysis bullosa (EB) is a heterogeneous group of rare, difficult-to-treat, inherited multisystem diseases affecting epithelial integrity. Patients with EB are affected by mechanical fragility of epithelial surfaces including the skin and, as a result, extensive recurrent blistering is a characteristic of the condition. Chronic wounds predispose patients with EB to the development of squamous cell carcinoma, which is a major cause of premature death. Objectives EASE was a double-blind, randomized, vehicle-controlled, phase III study to determine the efficacy and safety of the topical gel Oleogel-S10 (birch triterpenes) in EB. EASE was funded by Amryt Research Limited. Methods Patients with dystrophic EB, junctional EB or Kindler EB and a target partial-thickness wound lasting ≥ 21 days and < 9 months that was 10–50 cm2, were enrolled and randomized via computer-generated allocation tables 1 : 1 to Oleogel-S10 or control gel – both with standard-of-care dressings. Study gel was applied to all wounds at least every 4 days. The primary endpoint was the proportion of patients with first complete closure of target wound within 45 days. Results A total of 223 patients were enrolled and treated (109 treated with Oleogel-S10, 114 with control gel). The primary endpoint was met; Oleogel-S10 resulted in 41·3% of patients with first complete target wound closure within 45 days, compared with 28·9% in the control gel arm (relative risk 1·44, 95% confidence interval (CI) 1·01–2·05; P = 0·013). Adverse events (AEs) occurred with similar frequency for Oleogel-S10 (81·7%) compared with control gel (80·7%). AEs were predominantly of mild-to-moderate intensity (4·6% were severe). Conclusions Oleogel-S10 is the first therapy to demonstrate accelerated wound healing in EB. Oleogel-S10 was well -tolerated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Collagen VII plays a dual role in wound healing

Author

Nystrom, Alexander, Velati, Daniela, Mittapalli, Venugopal R., Fritsch, Anja, Kern, Johannes S., and Bruckner-Tuderman, Leena

Subjects
Wound healing -- Physiological aspects, Collagen -- Health aspects, Cellular signal transduction -- Research, Health care industry
Abstract

Although a host of intracellular signals is known to contribute to wound healing, the role of the cell microenvironment in tissue repair remains elusive. Here we employed 2 different mouse [...]

Published
2013
Full Text
View/download PDF

41. De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris ��� a systematic review

Author

McClatchy, Jessica, Yap, Tami, Koo, Kendrick, Kern, Johannes S, and Scardamaglia, Laura

Abstract

Introduction: This review assesses current evidence supporting dose de-escalated rituximab therapy in pemphigus vulgaris, compared to standard protocols. Primary outcome measures were remission and relapse rates. Adverse effects, cumulative steroid dosages, and serological markers of disease activity were also reported. Areas covered: A literature search was performed to look for reports describing the use of de-escalated rituximab therapy in pemphigus vulgaris. Results from heterogenous studies showed a large variation in remission and relapse rates. Complete remission rates from de-escalated treatment ranged from 41.7 to 100.0%, while rates in the control groups ranged from 60.0 to 90.9%. Relapse rates varied from 8.0 to 81.3% in the de-escalated group and from 0.0 to 72.4% in the control group. Of the 165 patients included in this report, only two major adverse effects were reported. Expert Opinion: Overall, dose de-escalated rituximab protocols reported to date appear effective and safe. However, it is unclear if treatment effect parallels that of standard regimens in regard to disease control in the long term. A lower limit of effective dosing for rituximab in pemphigus vulgaris has not yet been reached or defined. The role for and timing of repeated cycles of low-dose rituximab therapy require further exploration.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results